Thyrocare Technologies Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 8 Aug 2026 | Healthcare Services | Market Cap: ₹9.5K Cr
Thyrocare aims to maintain the strong growth trajectory seen in FY '25, having achieved 23% year-on-year consolidated revenue growth in Q3 driven by organic (19%) and inorganic (4%) growth. Thyrocare expects continued strong growth, with revenue growth much above the industry’s mid-teen growth rate, aiming to maintain the current high growth trajectory.
From Thyrocare Technologies Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹566
Market Cap
₹9.5K Cr
P/E Ratio
52.8
How does Thyrocare Technologies Ltd rank in Healthcare Services?
Compare Thyrocare Technologies Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Thyrocare Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹224 Cr, net profit ₹49 Cr.
Full financials →📊 Revenue & Sales Performance
- →Thyrocare aims to maintain the strong growth trajectory seen in FY '25, having achieved 23% year-on-year consolidated revenue growth in Q3 driven by organic (19%) and inorganic (4%) growth.
- →Franchise revenue grew 24% YoY, partnerships business grew 23% YoY, and radiology business increased 13% YoY.
- →Vimta Labs acquisition is stabilizing; expected quarterly revenue from Vimta to be INR 3-4 crores for next 4 quarters before potential growth.
- →Expansion in insurance-related partnerships is ongoing, contributing about 10-13% of partnership revenues with expectation to deepen further.
- →Tanzania operations, still nascent, show potential with 100+ healthcare partners; revenue currently modest but expected to grow over time.
- →Q4 likely to continue momentum with a focus on sustaining mid to high-teen growth rates.
- →Strategy focuses on menu expansion, network deepening across India, and enhancing partner value to drive future volume and revenue growth.
📈 Profitability & Margins
- →Thyrocare expects continued strong growth, with revenue growth much above the industry’s mid-teen growth rate, aiming to maintain the current high growth trajectory.
- →EBITDA margins are improving with a normalized consolidated EBITDA margin of around 30% and positive operating leverage.
- →Vimta acquisition currently shows an EBITDA loss (~INR 1.4 crore for the quarter), but losses are expected to reduce over the next 0.5 year toward zero.
- →ESOP non-cash charges impacting reported profits but expected to decline gradually after next few quarters as the vesting schedule progresses.
- →Depreciation includes a one-time INR 4.75 crore charge due to asset life revision; going forward, depreciation will stabilize.
- →Management optimistic about profit growth continuing despite recent margin pressures from acquisitions and increased expenses.
- →Overall, profit and EPS are expected to improve over the coming quarters as integrations stabilize and organic growth continues.
🏗️ Capital Expenditure Plans
💰 Fundraising & Capital Structure
- →There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
- →Rahul Guha explicitly confirms there is no dilution at Thyrocare, emphasizing the end of the Thyrocare ESOP program and clarifying that the increase in shares is due to vesting of ESOPs granted to employees, not fresh equity issuance.
- →The company has not discussed or contemplated any speculative reverse merger or related fundraising.
- →Capex plans are modest, with INR 25 crores estimated for FY '25 and no significant fresh capex planned for radiology; no need for large new funding rounds indicated.
- →The focus remains on organic growth, acquisitions, and improving margins without explicit plans for new equity or debt fundraisings.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Thyrocare Technologies Ltd Q3 FY25 results?
Thyrocare aims to maintain the strong growth trajectory seen in FY '25, having achieved 23% year-on-year consolidated revenue growth in Q3 driven by organic (19%) and inorganic (4%) growth. Thyrocare expects continued strong growth, with revenue growth much above the industry’s mid-teen growth rate, aiming to maintain the current high growth trajectory.
What is Thyrocare Technologies Ltd share price analysis?
Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Thyrocare Technologies Ltd planning capital expenditure?
Radiology Business: - No significant fresh capex planned; machines are old but still running.
Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.